FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)

View source ↗

Summary

FDA approved a supplemental application for CELLCEPT (mycophenolate mofetil) filed by Genentech, resulting in an approved change to the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Transplant Rejection
• Kidney Transplant Rejection
• Liver Transplant Rejection

Drugs mentioned

• CELLCEPT (mycophenolate mofetil hydrochloride)

Snippet

SUPPL AP for CELLCEPT (MYCOPHENOLATE MOFETIL)